Inflarx (NASDAQ:IFRX) Announces Earnings Results, Beats Estimates By $0.20 EPS

Inflarx (NASDAQ:IFRX) released its earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.20, MarketWatch Earnings reports.

Shares of IFRX opened at $8.60 on Friday. The business’s 50-day moving average price is $6.22 and its 200 day moving average price is $4.19. The stock has a market capitalization of $224.51 million, a P/E ratio of -3.89 and a beta of 0.53. Inflarx has a 1-year low of $2.17 and a 1-year high of $42.99.

IFRX has been the topic of a number of research analyst reports. BMO Capital Markets lifted their target price on Inflarx from $4.00 to $7.00 and gave the stock a “market perform” rating in a report on Thursday. Raymond James lifted their target price on Inflarx from $10.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday. ValuEngine raised Inflarx from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Finally, SVB Leerink lifted their price target on Inflarx from $4.00 to $7.00 and gave the stock a “hold” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

See Also: What Is An Exchange-Traded Fund (ETF)?

Earnings History for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with's FREE daily email newsletter.